Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Ono Pharmaceutical Co., Ltd.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
Completed pre-operative chemo radiotherapy followed by surgery
Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection
You may not be if
Diagnosed with cervical esophageal carcinoma
Diagnosed with Stage IV resectable disease
Did not receive concurrent chemoradiotherapy prior to surgery
Participants who have received a live/attenuated vaccine within 30 days of the first treatment
Clareo Health | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
